Sulfasalazine

Sulfasalazine is a sulfa derivative of mesalazine, used as an anti-inflammatory agent to treat bowel disease and rheumatoid arthritis. Sulfasalazine is a potent and specific inhibitor of nuclear factor kappa B (NF-κB), TGF-β and COX-2. Sulfasalazine induces ferroptosis, apoptosis and autophagy.

CAS No. 599-79-1

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
500mg	JPY 22000	国内在庫なし(納期7~10日)
1g	JPY 34000	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（17）

製品安全説明書

現在のバッチを見る：純度： 99.65%

99.65

Sulfasalazine関連製品

関連製品	Cl-amidine TAPI-1 Bindarit Ipilimumab (anti-CTLA-4) Pimecrolimus Tempol Amlexanox Anti-mouse CD8α-InVivo Tranilast Sinomenine Rituximab (anti-CD20) N-Acetylcysteine amide Geniposidic acid GI254023X Phenylbutazone Hydrocortisone acetate CORM-3 Bestatin (Ubenimex) ATP Acacetin Germacrone Oxymatrine Imiquimod Gastrodin Atractylenolide I Y-320 Amodiaquine hydrochloride Sinomenine hydrochloride Tomatidine Hydrochloride Thymoquinone Demethylzeylasteral (T-96) Lupeol Flufenamic acid Quercitrin Laquinimod Iguratimod Calycosin Sanguinarine Punicalagin Z-Guggulsterone Fenamic acid Tiragolumab (anti-TIGIT) Geniposide Diclofenac Epolamine Thymol Lodoxamide Tromethamine Jujuboside A PMX-53 6-Shogaol Isoliensinine Tiaprofenic acid Diclofenac Potassium Arachidonic acid Astragalin Linarin Isoliquiritin Coumarin Platycodin D Pipecolic acid Umbelliferone Thymopentin Salvianolic acid A VGX-1027 Sinigrin Fenoprofen calcium hydrate Isovitexin Buddlejasaponin IVb Fenoprofen Calcium Lysionotin Liensinine Ginsenoside CK Lentinan Wogonoside Bakuchiol Carnosol Madecassic acid Acetylharpagide Anwuligan Ginkgetin Eicosapentaenoic Acid (EPA) Avacopan Tryptanthrin Pranlukast Cortisone	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Bioactive Compound Library-Ⅱ	もっと見る

Immunology & Inflammation related阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Incubation Time	活性情報	PMID
HepG2	Function assay	1 hr	Inhibition of NF-kappaB activation expressed in TNFalpha-stimulated human HepG2 cells co-transfected with PPRE-Luc plasmid pretreated for 1 hr before TNFalpha challenge measured after 24 hrs by luciferase reporter gene assay, IC50=0.9μM	21889336
HepG2	Function assay	1 hr	Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay, IC50=0.9μM	21870831
HepG2	Function assay	1 hr	Inhibition of TNFalpha-induced NFkappaB transcriptional activity in human HepG2 cells pretreated for 1 hr before TNFalpha challenge by luciferase reporter gene analysis, IC50=0.9μM	22381047
HepG2	Function assay	1 hr	Inhibition of NF-kappaB expressed in human HepG2 cells assessed as inhibition of TNFalpha-induced luciferase activity preincubated for 1 hr followed by TNFalpha challenge measured after 1 hr by reporter gene assay, IC50=0.9μM	23031596
HepG2	Function assay	1 hr	Inhibition of TNF-alpha-induced NF-kappaB transcriptional activation in human HepG2 cells preincubated for 1 hr followed by TNF-alpha challenge measured after 1 hr by luciferase reporter gene assay, IC50=0.9μM	24314396
HEK293 Flp-In	Function assay	5 mins	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting, Ki=3μM	22541068
HEK293 Flp-In	Function assay	5 mins	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting, IC50=3μM	22541068
U2OS	Function assay	10 mins	Inhibition of HA-tagged human NTCP expressed in human U2OS cells assessed as reduction in [14C]taurocholate uptake preincubated for 10 mins followed by [14C] taurocholate addition and further incubation for 10 mins by scintillation counting method, IC50=9.6μM	31439379
HEK293 Flp-In	Function assay	5 mins	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting, Ki=11μM	22541068
HEK293 Flp-In	Function assay	5 mins	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting, IC50=12μM	22541068
U87	Function assay	15 mins	Inhibition of xc-cystine-glutamate antiporter-mediated cystine uptake in human U87 cells using L-[14C]cystine as substrate after 15 mins by liquid scintillation counting, IC50=30μM	21889337
HEK293 Flp-In	Function assay		Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting, Ki=0.53μM	22541068
HEK293 Flp-In	Function assay		Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting, IC50=0.56μM	22541068
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Sulfasalazine is a sulfa derivative of mesalazine, used as an anti-inflammatory agent to treat bowel disease and rheumatoid arthritis. Sulfasalazine is a potent and specific inhibitor of nuclear factor kappa B (NF-κB), TGF-β and COX-2. Sulfasalazine induces ferroptosis, apoptosis and autophagy.

Targets

NF-κB ^[4]

COX-2 ^[4]

TGF-β ^[4]

In Vitro
In vitro	Sulfasalazine, like methotrexate, enhances adenosine release at an inflamed site and that adenosine diminishes inflammation via occupancy of A2 receptors on inflammatory cells. ^[1] Sulfasalazine treatment for 4 hours inhibits kappaB-dependent transcription with an IC50 value of approximately 0.625 mM. Sulfasalazine (2.5 mM) results in cell death of T-lymphocytes in a dose- and time-dependent manner. Sulfasalazine but not 5ASA or sulfapyridine, strongly inhibits NF-kappaB activation and potently induces apoptosis in T-lymphocytes. ^[2] Sulfasalazine is cleaved into sulfapyridine and 5-aminosalicylic acid (5-ASA; mesalamine) by colonic bacteria, and the latter, too, is reported to suppress NF-kappaB activity. Sulfasalazine but not its cleaved form 5-ASA causes a dose-dependent inhibition of glioma growth, this effect is entirely attributable to the inhibition of cystine uptake via the system x(c)(-) cystine-glutamate transporter. Sulfasalazine inhibits cystine uptake causing a chronic depletion of intracellular GSH and consequently compromised cellular redox defense which stymied tumor growth. ^[3]

In Vivo
In Vivo	Sulfasalazine markedly decreases the number of leukocytes that accumulated in the inflamed (carrageenan, 2 mg/ml) air pouch in the murine air pouch model of inflammation. Sulfasalazine treatment promotes a marked increase in splenocyte 5-aminoimidazole-4-carboxamidoribonucleotide (AICAR) concentration, which is consistent with the in vitro observation that sulfasalazine inhibits AICAR transformylase. ^[1]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT06134388	Recruiting	Metastatic Colorectal Cancer	Tanta University	September 1 2023	Phase 3
NCT03487926	Active not recruiting	Major Depressive Episode\|Inflammatory Bowel Diseases	Centre for Addiction and Mental Health\|McMaster University	September 14 2022	--
NCT04720183	Completed	Healthy	Galapagos NV	January 11 2021	Phase 1
NCT01577966	Completed	Brain Tumor	University of Alabama at Birmingham	January 2012	Not Applicable

参考
[1] Gadangi P, et al. J Immunol, 1996, 156(5), 1937-1941. [2] Liptay S, et al. Br J Pharmacol, 1999, 128(7), 1361-1369. [3] Chung WJ, et al. J Neurochem, 1009, 110(1), 182-193. [4] E Chávez, et al. Hum Exp Toxicol . 2012 Sep;31(9):913-20. + 展開

参考

[4] E Chávez, et al. Hum Exp Toxicol . 2012 Sep;31(9):913-20.

+ 展開

化学情報

分子量	398.39	化学式	C₁₈H₁₄N₄O₅S
CAS No.	599-79-1	SDF	Download Sulfasalazine SDFをダウンロードする Download Sulfasalazine SDFをダウンロードする
Smiles	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 80 mg/mL ( (200.8 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):